Methods for predicting in vivo pharmacokinetics using data from in vitro assays.
about
Predicting lung dosimetry of inhaled particleborne benzo[a]pyrene using physiologically based pharmacokinetic modelingHigh-throughput screening in primary neuronsCombining the 'bottom up' and 'top down' approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical dataMicrosomal and Cytosolic Scaling Factors in Dog and Human Kidney Cortex and Application for In Vitro-In Vivo Extrapolation of Renal Metabolic ClearanceAlternative (non-animal) methods for cosmetics testing: current status and future prospects-2010.The role of aldehyde oxidase and xanthine oxidase in the biotransformation of a novel negative allosteric modulator of metabotropic glutamate receptor subtype 5.Assessment of algorithms for predicting drug-drug interactions via inhibition mechanisms: comparison of dynamic and static models.The role of quantitative ADME proteomics to support construction of physiologically based pharmacokinetic models for use in small molecule drug development.Mechanisms underlying food-drug interactions: inhibition of intestinal metabolism and transport.Impact of organic solvents on cytochrome P450 probe reactions: filling the gap with (S)-Warfarin and midazolam hydroxylationAddressing Early Life Sensitivity Using Physiologically Based Pharmacokinetic Modeling and In Vitro to In Vivo Extrapolation.Improved proteostasis in the secretory pathway rescues Alzheimer's disease in the mouse.Predicting drug-drug interactions: an FDA perspectiveApplication of mechanism-based CYP inhibition for predicting drug-drug interactions.Quantitative in vitro to in vivo extrapolation of cell-based toxicity assay results.Evaluation of the metabolism and hepatotoxicity of xenobiotics utilizing precision-cut slices.In vitro-in vivo extrapolation (IVIVE) for predicting human intestinal absorption and first-pass elimination of drugs: principles and applications.Exploring concepts of in vitro time-dependent CYP inhibition assays.Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions.Pharmacokinetic herb-drug interactions with traditional Chinese medicine: progress, causes of conflicting results and suggestions for future research.Predictions of bisphenol A hepatic clearance in the isolated perfused rat liver (IPRL): impact of albumin binding and of co-administration with naproxen.Pediatric Development of Bosentan Facilitated by Modeling and Simulation.Strategic use of plasma and microsome binding to exploit in vitro clearance in early drug discovery.Application of IVIVE and PBPK modeling in prospective prediction of clinical pharmacokinetics: strategy and approach during the drug discovery phase with four case studies.In vivo-in vitro-in silico pharmacokinetic modelling in drug development: current status and future directions.Induction of Th1-biased cytokine production by alpha-carba-GalCer, a neoglycolipid ligand for NKT cells.Impact of fraction unbound, CYP3A, and CYP2D6 in vivo activities, and other potential covariates to the clearance of tramadol enantiomers in patients with neuropathic pain.Prediction of drug-drug interactions with carbamazepine-10,11-epoxide using a new in vitro assay for epoxide hydrolase inhibition.Evaluation of Time Dependent Inhibition Assays for Marketed Oncology Drugs: Comparison of Human Hepatocytes and Liver Microsomes in the Presence and Absence of Human Plasma.A microfluidic hepatic coculture platform for cell-based drug metabolism studies.Complex disease-, gene-, and drug-drug interactions: impacts of renal function, CYP2D6 phenotype, and OCT2 activity on veliparib pharmacokinetics.Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates.IC50-based approaches as an alternative method for assessment of time-dependent inhibition of CYP3A4.Drug-drug interaction potential of marketed oncology drugs: in vitro assessment of time-dependent cytochrome P450 inhibition, reactive metabolite formation and drug-drug interaction prediction.Sources of interindividual variability in IVIVE of clearance: an investigation into the prediction of benzodiazepine clearance using a mechanistic population-based pharmacokinetic model.Metabolism of xenobiotics by aldehyde oxidase.
P2860
Q28595882-78C56503-C670-4882-8084-CF41271D892CQ28709230-A36262FB-8996-4606-8E7C-92BD8C304552Q30666721-A05D3687-1322-4205-9E6E-7285993B6957Q33588394-D8B7B045-EC7B-442F-B0B9-0C95D22BA83EQ34181630-77CFCFEA-BCC9-4EA8-8AAD-7529AE739BACQ34308549-23B060FC-5EA0-439D-A01A-83827DE39CCAQ34476096-8255624D-DD17-46EE-B5FA-A0987336752FQ35560052-7A9D8F73-0911-487F-B9EB-A87534F6E220Q36303746-5CB37917-AA27-4B56-AA96-EFD0994505E2Q36335452-D8F79144-D9C6-46E5-8159-5B3605497010Q36657666-403B6E25-E521-4823-A791-E029297EF89AQ36722167-EDE154A8-FDEE-46FD-8024-F6D5619010E2Q37214533-DA3E7898-2CDA-4500-9704-C95A49936D6EQ37494640-FB3C5F9E-CD0A-451B-B51C-442CD935DAC9Q38016204-AD11FE60-15BD-4C24-AE3B-7CCA5BE62B89Q38058138-C2D8CD02-E750-4EE3-A76A-7BF98874B6E6Q38131859-85E6A00F-9B8E-42EE-8D6C-DC9D2B680B58Q38164432-C150EECC-BB94-4405-BA44-F00AB1AAAACCQ38684505-16C7A43D-A0D9-4765-B5CA-02FFC7EDAAFDQ38750365-F6867424-66E6-40E6-99DA-FAA9B59CAB92Q38918303-865B1388-2B1D-4AE5-AA12-7665600B9893Q39025680-9E4267EA-DEA6-4EF2-B007-0BA8CD28F0BDQ39159148-6B4D7575-D057-4926-8B04-571620BFDB7CQ39666574-DB4E445F-47A9-4DAC-9518-BBF12C5065FFQ39730914-84DFCF81-1114-44F3-B268-FA117CDE051AQ39735626-2941E0AB-C8FD-4A49-BF09-349AC0FFF7E1Q39944445-A3F6DB7B-EA75-4804-8CA3-F0F1921DF11DQ39952608-79BCEEFA-6B01-4A95-975F-DAD9CAEC790EQ40003126-255C3B99-4A28-4E8A-85A6-ADABE79C9616Q41845201-F0AB56EA-4A40-4D21-BC9B-59373893239BQ41850697-6DBC743C-0D32-4104-B3D9-1864D65C4766Q42283688-21A3FC17-E680-4142-B948-2FDAB620E72CQ43129481-37D9C4B7-2580-41AA-ACB5-055A3D662C62Q45939780-4CAFA9B6-D8B8-4F27-992D-C9AF7FD1F774Q48276802-F5F47174-E14A-4BF4-AAF3-A1656BC1588FQ54319308-75968B3B-4FE4-4D72-BCF1-4B0A41EC428A
P2860
Methods for predicting in vivo pharmacokinetics using data from in vitro assays.
description
2008 nî lūn-bûn
@nan
2008 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Methods for predicting in vivo pharmacokinetics using data from in vitro assays.
@ast
Methods for predicting in vivo pharmacokinetics using data from in vitro assays.
@en
type
label
Methods for predicting in vivo pharmacokinetics using data from in vitro assays.
@ast
Methods for predicting in vivo pharmacokinetics using data from in vitro assays.
@en
prefLabel
Methods for predicting in vivo pharmacokinetics using data from in vitro assays.
@ast
Methods for predicting in vivo pharmacokinetics using data from in vitro assays.
@en
P1476
Methods for predicting in vivo pharmacokinetics using data from in vitro assays.
@en
P2093
J Brian Houston
P304
P356
10.2174/138920008786485164
P407
P577
2008-11-01T00:00:00Z